New anticoagulant strategies in ST elevation myocardial infarction: Trials and clinical implications
Authors McCann CJ, Menown IBA
Published 11 April 2008 Volume 2008:4(2) Pages 305—313
Conor J McCann, Ian BA Menown
Craigavon Cardiac Centre, Craigavon Area Hospital, Craigavon, Northern Ireland, UK
Abstract: New data have re-established the importance of anticoagulation of patients with ST segment elevation myocardial infarction (STEMI), both as an adjuvant to reperfusion therapy or in patients ineligible for reperfusion. Recent randomized trials have found newer agents to be superior to conventional unfractionated heparin. This article summarizes current understanding of the underlying pathophysiology of STEMI and provides a comprehensive review of emerging trial data for low molecular weight heparins, anti-factor Xa agents and direct thrombin inhibitors in this setting.
Keywords: myocardial infarction, treatment, anticoagulants
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]